Table 3 Threshold effect analysis of eGFR on uric acid levels using piece-wise linear regression
From: Efficacy of different urinary uric acid indicators in patients with chronic kidney disease
Model | Model I | Model II | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Various | Male | Female | Total | Male | Female | Total | |||||||||||
Crude β/OR (95%CI) | p value | Crude β/OR (95%CI) | p value | Crude β/OR (95%CI) | p value | Crude β/OR (95%CI) | p value | Crude β/OR (95%CI) | p value | Crude β/OR (95%CI) | p value | ||||||
FEur (%) | FEur (%) | ||||||||||||||||
eGFR< 28.9 | − 0.7 (− 0.8, − 0.6) | < 0.001 | eGFR< 8 | −4.5 (−5.6, −3.4) | < 0.001 | eGFR< 15.9 | − 1.4 (− 1.6, − 1.2) | < 0.001 | eGFR< 28.9 | − 0.7 (− 0.8, − 0.6) | < 0.001 | eGFR< 8 | − 4.5 (− 5.6, − 3.4) | < 0.001 | eGFR< 15.9 | − 1.4 (− 1.6, − 1.2) | < 0.001 |
eGFR≥28.9 | −0.0 (− 0.1, − 0.0) | 0.002 | eGFR≥8 | −0.1 (− 0.1, − 0.1) | < 0.001 | eGFR≥15.9 | −0.1 (− 0.1, − 0.0) | < 0.001 | eGFR≥28.9 | −0.0 (− 0.1, − 0.0) | 0.002 | eGFR≥8 | −0.1 (− 0.1, − 0.1) | < 0.001 | eGFR≥15.9 | −0.1 (− 0.1, − 0.0) | < 0.001 |
EurGF (μmol/L) | EurGF (μmol/L) | ||||||||||||||||
eGFR< 21.3 | − 5.1 (− 5.6, − 4.6) | < 0.001 | eGFR< 8 | −21.6 (− 26.4, − 16.8) | < 0.001 | eGFR< 15.3 | −7.6 (− 8.5, − 6.7) | < 0.001 | eGFR< 20.2 | −5.3 (− 5.9, − 4.8) | < 0.001 | eGFR< 13.9 | −8.8 (− 10.6, − 7.0) | < 0.001 | eGFR< 15.3 | − 7.6 (− 8.5, − 6.7) | < 0.001 |
eGFR≥21.3 | −0.3 (− 0.3, − 0.2) | < 0.001 | eGFR≥8 | − 0.5 (− 0.6, − 0.3) | < 0.001 | eGFR≥15.3 | −0.3 (− 0.4, − 0.3) | < 0.001 | eGFR≥20.2 | −0.3 (− 0.4, − 0.2) | < 0.001 | eGFR≥13.9 | −0.4 (− 0.6, − 0.3) | < 0.001 | eGFR≥15.3 | −0.4 (− 0.5, − 0.3) | < 0.001 |